Evaluating the Diabetes–Cardiology interface: a glimpse into the diabetes management of cardiology inpatients in western Sydney’s ‘diabetes hotspot’ and the establishment of a novel model of care

Ramy H. Bishay1,2,3,5,6*, Gideon Meyerowitz-Katz1, David Chandrakumar1, Rajini Jayaballa1, Tien-Ming Hng1,2,6, Mark Mclean1,2, Dilini Punchihewa1, Maiyoori Jeyaprakash1, David Burgess2,4, John Riskallah4 and Glen F. Maberly1,2,3

Abstract

Background: Approximately two-thirds of individuals presenting to emergency departments in Western Sydney have glucose dysregulation, accelerating their risk of cardiovascular disease (CVD). We evaluated the prevalence and management of type 2 diabetes (T2D) in cardiology inpatients in Western Sydney. A novel model of care between diabetes and cardiology specialist hospital teams (joint specialist case conferencing, JSCC) is described herein and aimed at aligning clinical services and upskilling both teams in the management of the cardiology inpatient with comorbid T2D.

Methods: Cardiology inpatients at Blacktown-Mount Druitt Hospital were audited during a 1-month period.

Results: 233 patients were included, mean age 64 ± 16 years, 60% were male, 27% overweight and 35% obese. Known T2D comprised 36% (n = 84), whereas 6% (n = 15) had a new diagnosis of T2D, of which none of the latter were referred for inpatient/outpatient diabetes review. Approximately, 27% (n = 23) and 7% (n = 6) of known diabetes patients suffered hyper- and hypoglycaemia, respectively, and 51% (n = 43) had sub-optimally controlled T2D (i.e. HbA1c > 7.0%); over half (51%, n = 51) had coronary artery disease. Only two patients were treated with an SGLT2 inhibitor and no patients were on glucagon like peptide-1 receptor analogues. The majority were managed with metformin (62%) and therapies with high hypoglycaemic potential (e.g., sulfonylureas (29%)) and in those patients treated with insulin, premixed insulin was used in the majority of cases (47%).

Conclusions: Undiagnosed T2D is prevalent and neglected in cardiology inpatients. Few patients with comorbid T2D and CVD were managed with therapies of proven cardiac and mortality benefit. Novel models of care may be beneficial in this high-risk group of patients and discussed herein is the establishment of the diabetes-cardiology JSCC service delivery model which has been established at our institution.

Keywords: In-patient diabetes, Health care delivery, Hypoglycaemia, SGLT-2 inhibitors, Incretin therapies, GLP-1 receptor analogues, Cardiovascular disease, Obesity, Cardiovascular mortality, Ischaemic heart disease

*Correspondence: ramy.bishay@health.nsw.gov.au
6 Department of Endocrinology, Clinical School Building, Level 3, Western Sydney University Blacktown Campus, Blacktown Hospital, Marcel Crescent, Blacktown, NSW 2148, Australia
Full list of author information is available at the end of the article

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Given that people with type 2 diabetes mellitus (T2D) are more than 2–3 times more likely to die of cardiovascular disease (CVD) than people without T2D [1, 2], treatment paradigms have favourably shifted from a ‘glucose lowering’ to a ‘cardioprotective’ model of care [3–5]. Recent cardiovascular safety and non-inferiority trials of newer diabetes therapies show cardiovascular neutrality with dipeptidyl peptidase-4 inhibitors (DPP4i [e.g., sitagliptin]) [6] however, there was demonstrable reduction in CV mortality and hospitalisation for heart failure (HF) with sodium-glucose co-transporter 2 inhibitors (SGLT2i [e.g., empagliflozin, canagliflozin, dapagliflozin]) [7–9], and CV events with glucagon-like peptide 1 receptor agonists (GLP1-RA [e.g., liraglutide, semaglutide]) [10, 11]; this is in addition to added benefits of modest weight loss and improvement in blood pressure also seen with these agents.

Considering the robust clinical evidence, the uptake of ‘cardioprotective therapies’ may not be as sweeping as once thought [12], especially in primary care. These reasons include the lack of clinical inertia, the physician’s unfamiliarity with the newer therapies and of monitoring mechanisms, cost, side-effect profile [13], and perceived invasiveness of the injectable GLP1-RA. Prescribing trends in the UK still favoured metformin as the first-line treatment for T2D among primary care physicians (83.6%) however, sulphonylureas remained the second most common drug (41.4%), [14] despite the 10–17% increase in CV mortality, events, and hypoglycaemia [3]; in contrast, GLP-1 RA were rarely prescribed first-line or after metformin and DPP4i were prescribed at a mediocre 15.4%. Insulin prescriptions remained stable at 20–24% [14]. There is unanimous agreement regarding the risk of hypoglycaemia in modern diabetes management, yet the same therapies (i.e., sulphonylureas, insulins) were being used widely in the community.

Western Sydney is recognised as having one of the most metabolically abnormal populations in Australia, with nearly two-thirds of all people being tested in tertiary hospital emergency departments having some form of glycaemic abnormality (38.4% with T2D, 27.4% with prediabetes) using glycosylated haemoglobin (Hba1c) measurements taken as part of a screening project [15]. Given the emphasis on CV outcomes with newer pharmacotherapies, this study focussed on admitted patients to the cardiology service. We hypothesised that the considerable metabolic burden of disease known in our region, would lead us to identify a large gap between evidence-based clinical management and real-world findings. Our aims were to evaluate the prevalence of metabolic disease in this cohort, audit the clinical and financial outcomes, and evaluate pharmacologic burden in those with T2D. Importantly, we endeavoured to capture the potential opportunities that exist in improving diabetes management in this high-risk group, with a view towards enhancing the collaboration between diabetes and cardiology services through joint specialist case conferencing (JSCC), a novel model of care that has been recently implemented in our unit (see “Discussion” section).

Methods

Electronic medical records
A 1-month retrospective audit was undertaken of all patients admitted under the Cardiology Service through the Emergency Department in the month of September 2016 in Blacktown Mt Druitt Hospital, Western Sydney Local Health District (New South Wales, Australia). The hospital uses electronic medical records for documentation such that all progress notes, medications, patient information and results of investigations (pathology and radiology) are collected and accessible via a secure user defined, login process.

Data collection
Data collected was de-identified and included basic demographic information, weight (overweight, body mass index [BMI] 25–29.9 kg/m²; obese, BMI ≥ 30 kg/m²) and as having either incident or known prediabetes (Hba1c 39 to 46 mmol/mol, 5.7–6.4%) or T2D (Hba1c ≥ 48 mmol/mol or 6.5%) based on established definitions. Duration of diagnosis, diabetes treatment and the presence of micro- (retinopathy, neuropathy, nephropathy) and macrovascular (CV disease, peripheral vascular, cerebrovascular disease) complications were also obtained.

Primary reasons for admission, presence of coronary artery disease (CAD), HF, left ventricular ejection fraction (LVEF), valvular disease, the presence of other comorbid cardiopulmonary disease, risk factors, medications and laboratory data were obtained from the history or investigations (e.g., angiogram, echocardiogram). Cost of the inpatient stay was determined using national weighted activity unit (NWAU), a nationally standardised costing of health service activity, as well as the presence of hyper- or hypoglycaemia. Engagement with the diabetes service (referrals to diabetes educator and/or endocrinology registrar) were also documented to assess service utilization. This study was approved by the local human research committee.

Exclusions
We excluded individuals with Type 1 diabetes, admissions for elective procedures (e.g., elective angiograms or percutaneous coronary interventions/angioplasty, DC
cardioversion for atrial fibrillation/flutter, to perform transthoracic echocardiograms, awaiting preparation for coronary artery bypass graft procedure) readmissions within the audit month, incorrect admissions under cardiology and individuals not admitted through the emergency department. Admissions for elective procedures were defined using hospital coding as any admission that had a code of "elective", no specific procedures were identified in the audit.

Statistical analysis
All statistical analysis was conducted using SPSS software. Continuous variables were compared using a standard t-test, and categorical variables using Chi squared methodology. Bonferroni’s method was used to control for multiple comparisons, with p-values presented after correction.

Results
Identified patients included 311 of which 235 were included in the analysis (51 excluded due to elective procedures, 25 when the exclusion criteria was applied); 136 were non-T2D and 99 had T2D (Table 1), indicating a prevalence of 42% for T2D. Study participants with T2D were more likely to be older, more overweight or obese and have a longer length of stay by nearly 2 days (43 h); gender distribution among T2D cohort was equal. The NW-AU also appeared to be higher in the T2D cohort were almost four times more likely to present with IHD (mostly ST segment elevation myocardial infarction, STEMI) and nearly twice the rates of stroke, previous PCI, HF and previous smoking as the non-diabetic group (all p < 0.0001; Table 1). The NW-AU appeared to be higher in the T2D versus non-T2D cohort, although this was not statistically significant (p = 0.07).

Despite half of the non-T2D population having prediabetes based on screening HbA1c, participants with T2D had higher prevalence of CAD (p = 0.024), hypertension (p < 0.001), and dyslipidaemia (p = 0.002) but similar rates of stroke, previous PCI, HF and previous smoking (all p > 0.05; Table 2). There was higher pharmacologic burden in T2D patients (p = 0.002), with higher use of aspirin, angiotensin II receptor blockers, and loop diuretics, although likely due to the small subgroup sample size none of these values were statistically significant (p > 0.05). Of note, there was low uptake of ACEI or ARB in patients with T2D comorbid HF (39%, data not shown).

Incident T2D cases were found in 14 patients (Table 3), of whom none were referred to the diabetes service or recommended for either general physician or specialist review on discharge; only a fraction had the diagnosis mentioned in their discharge letter (21%) or coded appropriately as a new diagnosis in the medical record (36%). Morbidity in the overall T2D cohort was high with micro- and macrovascular complications present in 40% and 63%, respectively. Referral to the diabetes service was low (9% of prevalent and 0% in incident cases). Most patients were managed with metformin and/or sulphonylureas being the second most common therapy prescribed, whereas SGLT2i and GLP1-RA were rarely prescribed and insulin use was dominated by premixed preparation (47%) with an out-of-target mean HbA1c (68 mmol/mol or 8.4%).

Table 1 Comparison of demographic, clinical and admission characteristics between study participants in those with and without type 2 diabetes mellitus

| Parameter                        | Non-T2D | T2D    | P-value |
|----------------------------------|---------|--------|---------|
| N                                | 136     | 99     |         |
| Male (N, %)                      | 85 (63%)| 54 (54%)| NS      |
| Mean age (years)                 | 62 ± 17 | 67 ± 13| <0.001* |
| Country of birth                 |         |        |         |
| Australia/NA                     | 88      | 84     | NS      |
| Europe                           | 17      | 19     | NS      |
| Asia                             | 10      | 15     | NS      |
| Middle East                      | 6       | 5      | NS      |
| India                            | 6       | 4      | NS      |
| Pacific Islands                  | 5       | 6      | NS      |
| Aboriginal/Torres Strait Islander| 3       | 1      | NS      |
| New Zealand                      | 3       | 1      | NS      |
| Africa                           | 1       | 1      | NS      |
| Overweight (BMI ≥ 25–29.9 kg/m²) | 41**    | 21**   | 0.001*  |
| Obese (BMI ≥ 30 kg/m²)           | 37**    | 45**   | 0.01*   |
| Pre-diabetes (N, %)              | 72 (53) | –      | –       |
| Body mass index (kg/m²)          | 28 ± 5  | 32 ± 8 | <0.001* |
| Glycosylated haemoglobin (HbA1c) | 39 ± 3  | 55 ± 9 | <0.001* |
| %                                | 5.7 ± 0.4 | 7.3 ± 1.3 |         |
| Admission details                |         |        |         |
| Primary reason for admission     |         |        |         |
| Chest pain                       | 35 (26) | 28 (29) | <0.0001*** |
| Ischaemic heart disease          | 7 (5)   | 21 (21)|         |
| Heart failure                    | 13 (10)| 18 (18)|         |
| Arrhythmias                      | 35 (26)| 9 (9)  |         |
| Other heart disease              | 24 (18)| 11 (11)|         |
| Other (deemed non-cardiac)       | 21 (15)| 12 (12)|         |
| Length of stay (hours)           | 101 ± 130 | 144 ± 140 | 0.01* |
| National weighted activity unit  | 1.35 ± 1.52 | 1.72 ± 1.46 | 0.07 |

Values are shown as N (%) and mean ± SD; T2D, type 2 diabetes mellitus. *denotes statistical significance at P value < 0.05; **indicates some data missing or not recorded; ***denotes significant differences in distribution using Chi square test (P value < 0.05). Values in parentheses indicate percentage of the cohort; NS not statistically significant.
Table 2 Comparison of cardiac history, risk factors and pharmacotherapy between study participants in those with and without type 2 diabetes mellitus

| Parameter                                                                 | Non-T2D | T2D     | P-value  |
|----------------------------------------------------------------------------|---------|---------|----------|
| N                                                                          | 136     | 99      |          |
| Coronary artery disease (N; %)                                            | 50 (37) | 51 (51) | 0.024*   |
| Stroke (N; %)                                                             | 8 (6)   | 12 (12) | NS       |
| Previous coronary revascularisation                                        | 33 (24) | 32 (32) |          |
| Percutaneous coronary intervention*                                        | 24 (18) | 23 (23) |          |
| Coronary artery graft surgery                                               | 12 (9)  | 14 (14) |          |
| Heart failure                                                              | 42 (31) | 33 (33) |          |
| Left ventricle ejection fraction ≤ 40%                                     | 51 ± 18 | 53.6 ± 15.6 |          |
| Previous arrhythmia                                                        | 49 (36) | 26 (26) |          |
| Valvular disease                                                           | 51 (38) | 36 (36) |          |
| Cardiopulmonary disease and other risk factors                             |         |         |          |
| Current smoker (N; %)                                                      | 23 (17) | 14 (14) | NS       |
| Ex-smoker (N; %)                                                           | 36 (26) | 32 (32) |          |
| Pulmonary hypertension                                                     | 18 (13) | 18 (18) |          |
| Hypertension                                                               | 80 (59) | 80 (80) | <0.001*  |
| Dyslipidaemia                                                              | 56 (41) | 61 (61) | 0.002*   |
| Total cholesterol (mmol/L)                                                 | 4.3 ± 1.3 | 4.0 ± 1.4 | NS       |
| LDL-c (mmol/L)                                                             | 2.4 ± 1.1 | 2.2 ± 1.9 |          |
| HDL-c (mmol/L)                                                             | 1.1 ± 0.2 | 0.9 ± 1.1 |          |
| Triglycerides (mmol/L)                                                     | 1.7 ± 0.8 | 3.3 ± 2.1 |          |
| Chronic obstructive pulmonary disease                                      | 9 (7)   | 10 (10) | NS       |
| Asthma                                                                     | 18 (13) | 14 (14) | NS       |
| Cardiac medications                                                        |         |         |          |
| Aspirin                                                                    | 38 (28) | 50 (50) | 0.002*   |
| Dual anti-platelet agents                                                  | 10 (7)  | 16 (16) | NS       |
| Clopidogrel                                                                | 13 (10) | 18 (18) |          |
| Prasugrel                                                                  | 1 (0.7) | 2 (2)   |          |
| Ticagrel                                                                   | 2 (1)   | 2 (2)   |          |
| Warfarin                                                                   | 5 (4)   | 5 (5)   |          |
| Non-vitamin K antagonist oral anticoagulants                               | 18 (13) | 9 (9)   |          |
| Nitrates                                                                   | 9 (7)   | 10 (10) |          |
| Ivabradine                                                                 | 2 (1)   | 3 (3)   |          |
| Digoxin                                                                    | 16 (12) | 5 (5)   |          |
| Beta-blockers                                                              | 44 (32) | 44 (44) |          |
| Alpha-blockers                                                             | 9 (7)   | 9 (9)   |          |
| Calcium channel blocker                                                    | 22 (16) | 22 (22) |          |
| Angiotensin converting enzyme inhibitors                                   | 31 (23) | 19 (19) |          |
| Angiotensin II receptor blockers                                           | 31 (23) | 44 (44) | 0.002*   |
| Thiazide diuretic                                                          | 9 (7)   | 12 (12) | NS       |
| Loop diuretic                                                              | 21 (15) | 32 (32) | 0.007*   |
| Aldosterone receptor blocker                                               | 10 (7)  | 11 (11) | NS       |
| Centrally-acting antihypertensive                                         | 1 (<1)  | 1 (1)   | <0.001*  |
| Statins                                                                    | 61 (45) | 73 (74) | NS       |
| Ezetimibe                                                                  | 8 (6)   | 12 (12) |          |

Values are shown as N (%) and mean ± SD; LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol. * denotes statistical significance at P value < 0.05; ** indicates some data missing or not recorded; *** denotes significant differences in distribution using Chi square test (P value < 0.05); T2D cohort—PCI revealed disease in 17 involving left anterior descending artery, 15 left circumflex, 14 right coronary artery, and 4 left main. Values in parentheses indicate percentage of the cohort; NS not statistically significant.
Very few patients had an accurate documentation of duration of diagnosis of T2D and therefore this was not included. In total, 6 patients had documented hypoglycaemia (BGL < 4.0 mmol/L) of whom all were on either insulin or sulphonylurea, and 35 experienced hyperglycaemia (BGL ≥ 14 mmol/L) during their hospital admission.

### Discussion

Nearly 70% of people with T2D will die of CVD [16] therefore, focussing efforts to intensify case detection and enhance diabetes management to positively affect the long-term quality of life and survival in T2D patients is a major health priority.

Our audit revealed that people with T2D made up nearly 2 in 5 cardiology inpatients (14% were new diagnoses) and that T2D participants were unsurprisingly more obese or overweight, have comorbid CAD, stroke and as well as higher pharmacologic use than the non-T2D cohort. They were also more likely to present with heart failure (10 vs 18%, p<0.0001, Table 1). In community-dwelling older adults (65–74 years—similar to our study mean age), national data reveals that among those with CVD, T2D was comorbid in 19.4%; conversely, those with T2D, CAD was present in 10.6%, HF in 8.2% and cerebrovascular disease in 2.4% [17]. In contrast, our study sample had nearly 5×, 4× and 5× the rates of CAD (51%), HF (33%) and cerebrovascular disease (stroke or TIA, 12%), suggesting the presence of increased disease burden due to hospital bias of admitted patients. We found that none of the incident and only 9% of prevalent T2D cases were referred for inpatient review (11% for outpatient review), illustrating the need to increase communication between the cardiology and diabetes services to better deliver care in this high-risk group.

Our study revealed that 47% of insulin-requiring patients were on premixed insulin, and that after metformin, sulphonylureas were the most commonly prescribed oral agent (29%). Both therapies are more likely to be associated with hypoglycaemia and weight gain, and adversely affect individuals with CVD, particularly given the association of hypoglycaemia with arrhythmia and sudden death [3, 18, 19], as well as the blunted hypoglycaemic awareness in the context of beta-blocker use in these patients.

In addition to positively improving glycaemic control, many of the ‘newer’ diabetes therapies (i.e., SGLT2i, GLP1-RA, DPP4i) have extra-glycaemic benefits, such as reduction in LDL-c, improvements in HDL-c, stabilisation of endothelial cells, reduction in inflammation, regulating adipokine release with the added benefits of weight loss [20]. The low uptake of these drugs suggests that these therapies are not being appropriately considered locally in CVD patients with T2D. In fact, the Food and Drug Administration added a cardiovascular mortality indication in 2016 for empagliflozin, and both semaglutide and liraglutide have shown CV benefits as noted previously [10, 11]. Consequently, national and international guidelines should give consideration to escalating these new therapies as second line treatment in preference over

| Parameter | N = 99 |
|-----------|--------|
| Incident T2D | 14 (14%) |
| Referred for inpatient diabetes review | 0/14 |
| New diagnosis mentioned in discharge letter | 3/14 (21%) |
| New diagnosis coded for in medical record | 5/14 (36%) |
| Recommended for endocrinology review after discharge | 0/14 |
| Known T2D | 85 (85%) |
| Referred for inpatient diabetes review | 9/85 (11%) |
| Diagnosis mentioned in discharge letter | 82/85 (96%) |
| Diagnosis coded for in medical record | 82/85 (96%) |
| Recommended for endocrinology review after discharge | 11/85 (13%) |
| Management of known T2D | 85 (85%) |
| Prevalent T2D | 85 (85%) |
| Hyperglycaemia | 23/85 (27%) |
| Hypoglycaemia | 6/85 (7%) |
| HbA1c > 7% (> 53 mmol/mol) | 43/85 (56%) |
| Microvascular complications | 40 (40%) |
| Peripheral neuropathy | 7 (7%) |
| Retinopathy | 5 (5%) |
| Nephropathy (2 on dialysis) | 46 (46%) |
| Macrovascular complications | 63 (63%) |
| Coronary artery disease | 51 (51%) |
| Ischaemic heart disease | 53 (53%) |
| Peripheral vascular disease | 6 (6%) |
| Carotid stenosis | 4 (4%) |
| Stroke/transient ischaemic attack | 12 (12%) |
| Diabetes treatment | |
| Metformin | 61 (62%) |
| Sulphonylurea | 29 (29%) |
| Dipeptidyl peptidase-4 inhibitor | 13 (13%) |
| Sodium glucose co-transporter 2 inhibitor | 2 (2%) |
| Glucagon-like peptide-1 receptor analogue | 0 |
| Acarbose | 0 |
| Thiazolidinediones | 0 |
| None | 26 (26%) |
| Insulin | 17 (17%) |
| Mean total daily dose (U) | 77.7 ± 53 |
| Basal (mean HbA1c 78 mmol/mol, 9.3%) | 4/17 (24%) |
| Premixed (mean HbA1c 68 mmol/mol, 8.4%) | 8/17 (47%) |
| Basal-bolus (mean HbA1c 56 mmol/mol, 7.3%) | 5/17 (29%) |
the use of sulphonylureas (and provide clear contraindications for the use of thiazolidinediones) for people with T2D and CVD.

We commenced this audit to establish a more comprehensive approach to the problem of CV morbidity and mortality in T2D patients, specifically with the use of a novel integrated model of care using JSCC. Joint Specialist Case Conferencing comprises of an integrated discussion about a patients’ diabetes management between the diabetes specialist, resident, diabetes educator, patient and primary care physician and is carried out in the primary care clinic for 30-min consultations per patient. We have previously shown that JSCC lead to benefits after a single visit to primary care physicians, including an absolute reduction of $-0.87\%$ in HbA1c and reductions in blood pressure, lipid profile and weight, and that the results were durable to 3-years [21].

Given that many cardiology inpatient services are primarily focused on the immediate management of acute and subacute emergencies, chronic conditions such as T2D may be overlooked. As such, we have similarly instituted JSCC with our cardiology hospital specialist team on a monthly basis in a modified format (i.e., patient not present but discussed in a round table setting with clinicians and diabetes educators and cardiology nurses present, see Fig. 1), with a focus on building capacity within the cardiology specialist team to better manage diabetes, with added benefits of increasing communication and collaboration between the departments. A protocol for the management of diabetes with a focus on cardiovascular outcomes is also being developed. A second follow-up audit is planned to assess the impact of this intervention in an age- and gender-matched cohort. Limitations of the study include its retrospective nature, which is inherent in audit-type studies, as well as lack of mortality data; follow-up studies are in progress.

**Conclusions**

Altogether, this audit reveals the high prevalence of T2D in one of the most metabolically challenging, populations in Australia where there is a high burden of concurrent CVD. Greater collaboration should be sought in all tertiary hospitals where both cardiology and diabetes teams co-exist and a format similar to the JSCC model described here be considered to strengthen the diabetes-cardiology clinical service interface. Cardioprotective diabetes therapies have a unique niche in the CV patient with concomitant T2D and should guide appropriate management to reduce mortality and morbidity in this high-risk group.
Abbreviations

ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BGL: blood glucose level; CAD: coronary artery disease; CAGS: coronary artery bypass graft surgery; CDE: certified diabetes educator; COPD: chronic obstructive pulmonary disease; CV: cardiovascular; CVD: cardiovascular disease; DAPT: dual antiplatelet therapy; DPP4i: dipeptidyl peptidase-4 inhibitors; GLP1-RA: glucagon-like peptide-1 receptor analogues; HbA1c: glycosylated haemoglobin; HDL-c: high density lipoprotein cholesterol; HF: heart failure; HTN: hypertension; IHD: ischaemic heart disease; ISMN: isosorbide mononitrate; JMO: junior medical officer; JSCC: joint specialist case conferencing; LDL-c: low density lipoprotein cholesterol; LOS: length of stay; LVEF: left ventricular ejection fraction; NOAC: non-vitamin K antagonist oral anticoagulants; NWAU: national weighted activity unit; PCI: percutaneous coronary intervention; PVD: peripheral vascular disease; SGLT2i: sodium glucose co-transporter 2 receptor inhibitors; STEMI: ST segment elevation myocardial infarction; T2D: type 2 diabetes mellitus; TIA: transient ischaemic attack.

Authors’ contributions

RHB, GMK, DC, and GFM made substantial contribution to the conception and design as well as analysis and interpretation of data; RHB and GFM were involved in the drafting the manuscript for important intellectual content and gave final approval of the publishable version; RJ, TMH and KM were involved in revising the clinical and statistical information critically for content from an endocrinology and diabetes perspective whereas JR and DB were involved in the clinical cardiology aspects of interpretation and analysis as well as discussion; DP and MJ were involved in data acquisition; all authors agreed to be accountable for all aspects of the work including its accuracy and integrity. All authors read and approved the final manuscript.

Author details

1 Western Sydney Diabetes, Integrated and Community Health Directorate, Department of Endocrinology and Diabetes, Blacktown Hospital, Western Sydney Local Health District, Sydney, NSW, Australia. 2 School of Medicine, Western Sydney University, Sydney, NSW, Australia. 3 School of Medicine, University of Sydney, Sydney, NSW, Australia. 4 Department of Cardiology, Blacktown Hospital, Blacktown, NSW, Australia. 5 Metabolic and Weight Loss Program, Blacktown Hospital, Western Sydney Local Health District, Sydney, NSW, Australia. 6 Department of Endocrinology, Clinical School Building, Level 3, Western Sydney University, Blacktown Campus, Blacktown Hospital, Marcel Crescent, Blacktown, NSW 2148, Australia.

Acknowledgements

None.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The data used to support the findings of this study are restricted to the Western Sydney Local Health Research committee to protect patient privacy. Data are available from Dr Ramy H Bishay (see above contact information for correspondence) for researchers who meet the criteria for access to confidential data.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The retrospective study was approved by the Western Sydney Local Health District Human Research Ethics Committee.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Baena-Diez JM, Penafiel J, Subirana I, Ramos R, Elosua R, Marin-Ibanez A, et al. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care. 2016;39(11):1987–95.

2. Centers for Disease Control and Prevention UDoHaHS. Centers for Disease Control and Prevention. Atlanta, 2017.

3. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013;30(10):1160–71.

4. Gorter PM, Visseren FL, Algra A, van der Graaf Y, Group SS. The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study. Diabet Med. 2007;24(12):1532–60.

5. Chang YC, Chuang LM, Lin JW, Chen ST, Lai MS, Chang CH. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. Diabet Med. 2015;32(11):1460–9.

6. Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, et al. Assessing the safety of sitagliptin in older participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care. 2014;40(4):494–501.

7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

8. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

9. Persson F, Nystrom T, Jorgensen ME, Carstensen B, Gulseth HL, Thureson M, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2017;20:344–51.

10. Marso SP, Daniels GH, Brown-Flandres K, Kristensen P, Mann JF, Nauck MA, et al. Lioglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

11. Marso SP, Bain SC, Consoili A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

12. Bajaj HS, Zinman B. Cardiovascular outcome trials in diabetes: will the EMPA-REG OUTCOME and LEADER trials influence clinical decisions in type 2 diabetes? Can J Diabetes. 2016;40(5):379–81.

13. Strain WD, Bluhmer M, Paldanius P. Clinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes? Diabetes Ther. 2014;5(2):347–54.

14. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):e010210.

15. Hng TM, Hor A, Ravi S, Feng X, Lin J, Astell-Burt T, et al. Diabetes case finding in the emergency department, using HbA1c: an opportunity to improve diabetes detection, prevention, and care. BMJ Open Diabetes Res Care. 2016;4(1):e000191.

16. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010;33(2):442–9.

17. Statistics. ABo. Information paper: National Health Survey-Confidentialised Unit Record Files, Australia, 2004–05. Canberra: ABS, August 2007. Contract No.: ABS cat. no. 4324.0.

18. Riddle MC, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab. 2014;16(5):396–402.

19. Leonardi CE, Hennessy S, Han X, Siscovick DS, Flory JH, Deo R. Pro- and antiarrhythmic actions of sulfonylureas: mechanistic and clinical evidence. Trends Endocrinol Metab. 2017;28(8):561–86.
20. Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288–96.
21. Meyerowitz-Katz G, Bramwell SJ, Jayaballa R, Bishay R, Corless I, Sumathy R, Soars L, Xiaoqi F, Astell-Burt T, Manoharan M, McLean M, Maberly GF. Effectiveness of joint specialist case conferences for building general practice capacity to enhance diabetes care: a pilot study in Western Sydney, Australia. J Integ Care. 2018;26(3):199–210.